Date | Title | Description | |
---|---|---|---|
27 Feb 2024 | On P&L | The Company releases the press release related to the full year 2023 financial results. | Download |
27 Feb 2024 | On P&L | The Company releases the full year 2023 financial results presentation. | Download |
27 Feb 2024 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
08 Nov 2023 | On P&L | The Company releases the press release related to the first nine months of 2023 financial results | Download |
08 Nov 2023 | On P&L | The Company releases the first nine months 2023 financial results presentation | Download |
Pages
Date | Title | Description | |
---|---|---|---|
05 Nov 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted on 3 and 4 November | Download |
03 Nov 2021 | On business and financial situation | The Company releases the first nine months 2021 financial results presentation | Download |
03 Nov 2021 | On business and financial situation | The Company releases the press release related to the first nine months 2021 financial results | Download |
21 Oct 2021 | Liquidity and counterparty agreements | Download | |
21 Oct 2021 | On business and financial situation | The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). | Download |
Pages
Date | Title | Description | |
---|---|---|---|
27 Feb 2014 | Informe anual de remuneraciones de consejeros 2013 | Download | |
27 Nov 2013 | Acuerdos estratégicos con terceros | Download | |
26 Nov 2013 | Acuerdos estratégicos con terceros | Download | |
07 Nov 2013 | Información sobre resultados (4) | Download | |
07 Nov 2013 | Información sobre resultados (3) | Download |